All
Burning the Midnight Oil: Night Shift Work May Increase Cancer Risk
January 19th 2018Research constantly highlights how adequate sleep impacts health outcomes. A recent meta-analysis, published in Cancer Epidemiology, Biomarkers & Prevention, delved in a bit further to see if people who stayed up all night for work had an increased chance of developing cancer.
Monitoring for AML Remissions: Are We Measuring Properly?
January 18th 2018So, wouldn't it be nice to have a quantitative way to say how deep the remission is? Historically, it’s been felt that if you just scratch the surface and get below the 5 percent blast level, you’re probably going to relapse. And if you get deeper, you might not.
Kyprolis Label Update Approved for Myeloma Treatment
January 18th 2018The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.
Beta Blockers May Lower Stress, Help Boost Immunotherapy Treatment Response
January 18th 2018A study, conducted at Penn State College of Medicine, demonstrated that patients with melanoma who received immunotherapy while also taking a specific type of beta blocker lived longer than those who received immunotherapy alone.
Despite Clinical Efficacy, Only Certain Myeloma Treatments Are Cost-Effective
January 17th 2018Over the past few years, the Food and Drug Administration (FDA) has approved a variety of triplet combinations for the treatment of patients with multiple myeloma. However, little is known which regimens have the best economic impact, without sacrificing clinical outcomes that is.
CAR-T Cell Therapy Gets Priority Review for Lymphoma Treatment
January 17th 2018The Food and Drug Administration granted a priority review to a supplemental biologics license application for Kymriah (tisagenlecleucel) to be used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma who either relapse or are not eligible for an autologous stem cell transplant.
Molecular Testing Is Key in Understanding MSI-H Colorectal Cancer
January 16th 2018In recent years, next-generation sequencing has allowed physicians and researchers alike to gather more genetic data for patients with gastrointestinal cancers. And while this kind of profiling continues to advance, so do treatment options for this patient population.
Gilotrif's Approval Expanded to Some Patients With Metastatic NSCLC
January 15th 2018The Food and Drug Administration (FDA) expanded the approved use for Gilotrif (afatinib). The drug can now be used to treat patients with metastatic non-small cell lung cancer (NSCLC) who have uncommon EGFR alterations in L861Q, G719X and/or S768I.
FDA Approves Lynparza for BRCA-Positive Breast Cancer
January 12th 2018Lynparza (olaparib) was granted approval by the Food and Drug Administration (FDA) for the treatment of patients with BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. Also, patients who have HR-positive disease should have prior endocrine therapy or they would not be considered appropriate for such treatment.